| 1. |
Otto CM, Lind BK, Kitzman DW, et al. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med, 1999, 341(3): 142-147.
|
| 2. |
Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet, 2006, 368(9540): 1005-1011.
|
| 3. |
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol, 2021, 77(4): 450-500.
|
| 4. |
中國醫師協會心血管內科醫師分會結構性心臟病專業委員會. 經導管主動脈瓣置換術中國專家共識(2020 更新版). 中國介入心臟病學雜志, 2020, 28(6): 301-309.
|
| 5. |
Bana A. TAVR-present, future, and challenges in developing countries. Indian J Thorac Cardiovasc Surg, 2019, 35(3): 473-484.
|
| 6. |
Steine K, Rosseb? AB, Stugaard M, et al. Left ventricular systolic and diastolic function in asymptomatic patients with moderate aortic stenosis. Am J Cardiol, 2008, 102(7): 897-901.
|
| 7. |
Mentias A, Saad M, Girotra S, et al. Impact of pre-existing and new-onset atrial fibrillation on outcomes after transcatheter aortic valve replacement. JACC Cardiovasc Interv, 2019, 12(21): 2119-2129.
|
| 8. |
Tarantini G, Mojoli M, Windecker S, et al. Prevalence and impact of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis from the SOURCE XT prospective multicenter registry. JACC Cardiovasc Interv, 2016, 9(9): 937-946.
|
| 9. |
Tarantini G, Mojoli M, Urena M, et al. Atrial fibrillation in patients undergoing transcatheter aortic valve implantation: epidemiology, timing, predictors, and outcome. Eur Heart J, 2017, 38(17): 1285-1293.
|
| 10. |
Moreno R, Calvo L, Salinas P, et al. Causes of peri-operative mortality after transcatheter aortic valve implantation: a pooled analysis of 12 studies and 1223 patients. J Invasive Cardiol, 2011, 23(5): 180-184.
|
| 11. |
Biviano AB, Nazif T, Dizon J, et al. Atrial fibrillation is associated with increased mortality in patients undergoing transcatheter aortic valve replacement: insights from the placement of aortic transcatheter valve (PARTNER) trial. Circ Cardiovasc Interv, 2016, 9(1): e002766.
|
| 12. |
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the heart rhythm society. J Am Coll Cardiol, 2019, 74(1): 104-132.
|
| 13. |
Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med, 1996, 156(22): 2537-2541.
|
| 14. |
Bogunovic N, Scholtz W, Prinz C, et al. Percutaneous closure of left atrial appendage after transcatheter aortic valve implantation - an interventional approach to avoid anticoagulation therapy in elderly patients: TAVI and closure of LAA to avoid warfarin therapy. Eurolntervention, 2012, 7(11): 1361-1363.
|
| 15. |
Sinning JM, Hammerstingl C, Vasa-Nicotera M, et al. Transcatheter aortic valve implantation and closure of the left atrial appendage under cerebral protection. EuroIntervention, 2012, 8(5): 640-641.
|
| 16. |
Khattab AA, Gloekler S, Sprecher B, et al. Feasibility and outcomes of combined transcatheter aortic valve replacement with other structural heart interventions in a single session: a matched cohort study. Open Heart, 2014, 1(1): e000014.
|
| 17. |
Attinger-Toller A, Maisano F, Senn O, et al. “One-stop shop”: safety of combining transcatheter aortic valve replacement and left atrial appendage occlusion. JACC Cardiovasc Interv, 2016, 9(14): 1487-1495.
|
